Background
==========

The exacerbation of malaria in sub-Saharan Africa towards the end of the 20th century accrued from amplified resistance to chloroquine and sulfadoxine-pyrimethamine (SP) the most affordable antimalaria medicines \[[@B1]\]. Contact with substandard antimalarial medicines probably aggravated this development \[[@B2]-[@B4]\]. Pressure from malaria scientists triggered extensive acceptance and implementation of artemisinin-based combination therapies (ACTs) by endemic country governments and donors \[[@B5]\]. All medicines carry some risk of harm and it is important to monitor their intended and unwanted effects for good evidence upon which to base an assessment of risk versus effectiveness or risk versus benefit. Furthermore, particularly with new medicines, the early identification of unexpected adverse reactions and their risk factors is essential, so that the medicines can be used in an informed manner with the least chance of harm. This is the role of pharmacovigilance (PV). Information gathered during pharmacovigilance may also assist in selecting the most appropriate medicine for future use. The objectives of this study were to document the suspected undesirable but common adverse drug reactions (SADRs) of patients using various Artemisinin-based Combination therapies (ACTs) in Lagos, (Nigeria) and to document the involvement of community pharmacists in the detection and reporting of these ADRs.

Materials and methods
=====================

A semi-structured questionnaire was served to each of the 235 randomly selected community pharmacists/respondents in urban and semi-urban Lagos metropolis between May and July 2008 out of which 201 (83.8%) responded.

Results
=======

Nine hundred and sixty one reports of SADR to Artesunate-Amodiaquine (AA) combination were reported followed by 642 to dihydro-artemisinin-SP combination, 521 to Artesunate-Mefloquine combination, 401 to Artemisinin monotherapies and 401 to Artemeter-Lumefantrin combination (Table [1](#T1){ref-type="table"}). When Artesunate Amodiaquine was compared with Artemeter Lumefantrin, there were significant differences in the proportion of patients with weakness and fatigue (102, 37.8%; 32, 11.9%; OR 4.52; p\<0.0001), dizziness (93, 38.0%; 32, 12.1%; OR 4.07; p\<0.0001), headache (51, 27.9%; 25, 13.7%; OR 2.44; p\<0.0001), insomnia (46, 36.5%; 13, 10.3%; OR 5.00; p\<0.0001), abdominal discomfort (52, 28.5%; 30, 17.0%; OR 1.6; p\<0.05) and depression (14, 44.1%; 3, 8.8%; OR 8.16; p\<0.0001).

###### 

Proportion of patients with suspected adverse drug reactions (SADRs) to various Artemisinin-based combination therapies (ACT) in Lagos (2008).

  SADRs                    Artemisinin Monotherapy (number of reports=410)   Artesunate-Mefloquine (number of reports=521)   Artesunate-Amodiaquine (number of reports=961)   Artemeter-Lumefantrine (number of reports=401)   Dihydro artemisinin/SP (number of reports=642)
  ------------------------ ------------------------------------------------- ----------------------------------------------- ------------------------------------------------ ------------------------------------------------ ------------------------------------------------
  Anorexia                 19                                                25                                              52                                               14                                               33
  Tightening of chest      7                                                 17                                              26                                               13                                               9
  Rashes                   10                                                21                                              28                                               20                                               55
  Pruritis                 6                                                 *22*                                            39                                               16                                               28
  Dizziness                33                                                48                                              93                                               32                                               39
  Restlessness             35                                                35                                              79                                               24                                               29
  Headache                 39                                                31                                              51                                               25                                               37
  General body pain        19                                                24                                              43                                               16                                               18
  Weakness/fatigue         43                                                47                                              102                                              32                                               46
  Vomiting                 5                                                 11                                              15                                               5                                                20
  Abdominal discomfort     37                                                25                                              52                                               30                                               32
  Insomnia                 17                                                21                                              46                                               13                                               29
  Swollen/blistered lips   9                                                 6                                               10                                               11                                               46
  Hallucination            3                                                 17                                              16                                               9                                                14

Conclusions
===========

Suspected adverse drug reactions especially to AA are factors that limit its use as an effective ACT which has unpalatable reactions to the patient. The confidence of end users of this particular ACT wanes with the development of suspected but constant mild, moderate to severe adverse drug reactions.
